150 related articles for article (PubMed ID: 32939326)
1. Firing up the cold tumors by targeting Vps34.
Janji B; Hasmim M; Parpal S; Berchem G; Noman MZ
Oncoimmunology; 2020 Aug; 9(1):1809936. PubMed ID: 32939326
[TBL] [Abstract][Full Text] [Related]
2. Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.
Janji B; Hasmim M; Parpal S; De Milito A; Berchem G; Noman MZ
Autophagy; 2020 Nov; 16(11):2110-2111. PubMed ID: 32892693
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Noman MZ; Parpal S; Van Moer K; Xiao M; Yu Y; Viklund J; De Milito A; Hasmim M; Andersson M; Amaravadi RK; Martinsson J; Berchem G; Janji B
Sci Adv; 2020 May; 6(18):eaax7881. PubMed ID: 32494661
[TBL] [Abstract][Full Text] [Related]
4. "Suffocating" tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy.
Janji B; Chouaib S
Oncoimmunology; 2021; 10(1):1968611. PubMed ID: 34527430
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
7. A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
Zhou F; Li X; Xue X; Li S; Fan G; Cai Y; Chang Z; Qu J; Liu R
Adv Healthc Mater; 2023 Apr; 12(11):e2202757. PubMed ID: 36652763
[TBL] [Abstract][Full Text] [Related]
8. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
[TBL] [Abstract][Full Text] [Related]
9. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
Reschke R; Yu J; Flood B; Higgs EF; Hatogai K; Gajewski TF
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593622
[TBL] [Abstract][Full Text] [Related]
10. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Oweida A; Lennon S; Calame D; Korpela S; Bhatia S; Sharma J; Graham C; Binder D; Serkova N; Raben D; Heasley L; Clambey E; Nemenoff R; Karam SD
Oncoimmunology; 2017; 6(10):e1356153. PubMed ID: 29123967
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Majidpoor J; Mortezaee K
Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
[TBL] [Abstract][Full Text] [Related]
12. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
13. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
17. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
19. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
20. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
